NanoVelos Overview

  • Year Founded
  • 2013

Year Founded

  • Status
  • Private

  • Employees
  • 4

Employees

  • Latest Deal Type
  • Early Stage VC

  • Latest Deal Amount
  • $1.12M

  • Investors
  • 7

NanoVelos General Information

Description

Developer of cancer treatment drugs designed to create a method of coating active substances with nano-particles of polysaccharides. The company's technology transforms generics to super-generics via a dextran-based nano-particle delivery system and exhibits dramatically improved tumor targeting, enabling medical professionals to enhance therapeutic efficacy while minimizing adverse effects on healthy tissues.

Contact Information

Website
www.nanovelos.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • Rakowiecka 36
  • Room 260
  • Warsaw, 02-532
  • Poland
Primary Industry
Drug Delivery
Other Industries
Biotechnology
Vertical(s)
Nanotechnology, Life Sciences, Oncology
Corporate Office
  • Rakowiecka 36
  • Room 260
  • Warsaw, 02-532
  • Poland

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

NanoVelos Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Early Stage VC 16-Dec-2017 $1.12M Completed Generating Revenue
3. Early Stage VC 01-Jul-2015 Completed Generating Revenue
2. Grant $347K Completed Startup
1. Early Stage VC 10-Apr-2013 Completed Startup
To view NanoVelos’s complete valuation and funding history, request access »

NanoVelos Patents

  • 13

    Total Documents Applications and Grants

  • Total Patents Families

  • 11

    Granted

  • 1

    Pending

  • Expiring in next 12 mo

NanoVelos Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-3761955-A1 Anthracycline encapsulated with polysaccharide for use in the treatment of tumours Pending 06-Mar-2018
US-20210052616-A1 Anthracycline encapsulated with a polysaccharide for use in the treatment of tumours Inactive 06-Mar-2018
ES-2780387-T3 Procedure for the preparation of polysaccharide nanoparticles Active 14-Mar-2012
CA-2866682-A1 Process for the preparation of polysaccharide nanoparticles Active 14-Mar-2012
US-10258579-B2 Process for the preparation of polysaccharide nanoparticles Active 14-Mar-2012 C08B1/12
To view NanoVelos’s complete patent history, request access »

NanoVelos Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

NanoVelos Investors (7)

Investor Name Investor Type Holding Investor Since Participating Rounds
ZernikeMeta Ventures Venture Capital Minority
Angel (individual) Minority
PFR Ventures Limited Partner Minority
Giza Polish Ventures Venture Capital Minority
Krajowy Fundusz Kapitałowy Fund of Funds Minority
You’re viewing 5 of 7 investors. Get the full list »

Ready to get started?

Request a free trial

NanoVelos FAQs

  • When was NanoVelos founded?

    NanoVelos was founded in 2013.

  • Where is NanoVelos headquartered?

    NanoVelos is headquartered in Warsaw, Poland.

  • What is the size of NanoVelos?

    NanoVelos has 4 total employees.

  • What industry is NanoVelos in?

    NanoVelos’s primary industry is Drug Delivery.

  • Is NanoVelos a private or public company?

    NanoVelos is a Private company.

  • What is the current valuation of NanoVelos?

    The current valuation of NanoVelos is .

  • What is NanoVelos’s current revenue?

    The current revenue for NanoVelos is .

  • How much funding has NanoVelos raised over time?

    NanoVelos has raised $1.12M.

  • Who are NanoVelos’s investors?

    ZernikeMeta Ventures, , PFR Ventures, Giza Polish Ventures, and Krajowy Fundusz Kapitałowy are 5 of 7 investors who have invested in NanoVelos.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »